focus -WSS

focus

author：leisure time 2025-09-30 16:59:53 - browse：93

Ron Wyden (left), Mike Crapo (right) -- health policy coverage from STAT — Draft legislation authored by Senate Finance Chair Ron Wyden (D-Ore.) and ranking member Mike Crapo (R-Idaho) includes several measures to regulate how pharmacy benefit managers are paid by health plans to negotiate with drugmakers. Pete Marovich-Pool/Getty Images

WASHINGTON — A key Senate health care panel has developed a plan to tackle reforms to middlemen in the pharmacy drug payment system, according to bill text obtained by STAT.

The draft legislation, authored by Senate Finance Chair Ron Wyden (D-Ore.) and ranking member Mike Crapo (R-Idaho), includes several measures to regulate how pharmacy benefit managers are paid by health plans to negotiate with drugmakers.

The most significant measure is a bill from Sens. Bob Menendez (D-N.J.) and Marsha Blackburn (R-Tenn.) that would prohibit PBMs from getting any income outside of service fees, and prohibits those service fees from being related to drugs’ list prices.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： The best solution to the drug shortages problem

WSS

Amylyx's ALS drug launch starts strong. It could be trouble for FDA

Prescription digital therapeutics are key to pharma’s future

What affirmative action's end means to a medical student

What affirmative action's end means to a medical student

Undocumented workers face uncertainty as immigration law takes effect in Florida

Skip the lead apron during X

leisure time

focus

hotspot

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

What affirmative action's end means to a medical student

Sports medicine is finally prioritizing gender equality

Beware reading your test results before your doctor does

In age of alternative facts, a scholarly course on calling out crap

Crowdfunding for unproven stem cell procedures spreads misinformation

Moonlake's readout produced a cash windfall. Risks remain

Listen: Merck v. USA, the best of ASCO, and Leqembi at the FDA

Wildfire smoke exposes gaps in outdoor worker protections

The wait for US passports is creating travel purgatory and snarling summer plans

Wikipedia

Anavex keeps shifting the goalposts in its clinical trials

Prescription digital therapeutics are key to pharma’s future

A biotech analyst on neuroscience, placebo effect, not over

Anavex keeps shifting the goalposts in its clinical trials

What affirmative action's end means to a medical student

Naloxone nonprofit donates 200,000 doses after FDA approval

entertainment

entertainment

focus

Wikipedia